M. Paff

Most-cited papers

1. The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine

   P. Furman, Michelle G. Davis, D. C. Liotta, M. Paff +6 more

   1992Antimicrobial Agents and Chemotherapy212 citations Open access

   Semantic Scholar

   Save

2. Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection.

   Man-Fung Yuen, Seng G. Lim, R. Pleśniak, K. Tsuji +30 more

   2022New England Journal of Medicine209 citations Open access

   Semantic Scholar

   Save

3. Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial

   Man-Fung Yuen, J. Heo, J. Jang, Jung-Hwan Yoon +13 more

   2021Nature Medicine141 citations Open access

   Semantic Scholar

   Save

4. 2-Amino-6-methoxypurine arabinoside: an agent for T-cell malignancies.

   C. U. Lambe, D. Averett, M. Paff, John E. Reardon +2 more

   1995Cancer Research94 citations

   Semantic Scholar

   Save

5. In vivo antiviral activity and pharmacokinetics of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in woodchuck hepatitis virus-infected woodchucks

   John M. Cullen, Sheila L. Smith, Michelle G. Davis, Sandra E. Dunn +8 more

   1997Antimicrobial Agents and Chemotherapy56 citations Open access

   Semantic Scholar

   Save

6. High-performance liquid chromatography method for the determination and quantitation of arabinosylguanine triphosphate and fludarabine triphosphate in human cells.

   C. Rodriguez, W. Plunkett, M. Paff, M. Du +4 more

   2000Journal of Chromatography B: Biomedical Sciences and Applications53 citations

   Semantic Scholar

   Save

7. Sequential Peg-IFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis B.

   Maria Buti, J. Heo, Yasuhito Tanaka, Pietro Andreone +33 more

   2024Journal of Hepatology52 citations Open access

   Semantic Scholar

   Save

8. Intracellular metabolism of (-)- and (+)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in HepG2 derivative 2.2.15 (subclone P5A) cells

   M. Paff, D. Averett, K. Prus, Wayne H. Miller +1 more

   1994Antimicrobial Agents and Chemotherapy49 citations Open access

   Semantic Scholar

   Save

9. Antiviral, metabolic, and pharmacokinetic properties of the isomeric dideoxynucleoside 4(S)-(6-amino-9H-purin-9-yl)tetrahydro-2(S)-furanmethanol

   V. Nair, M. St Clair, J. E. Reardon, H. C. Krasny +6 more

   1995Antimicrobial Agents and Chemotherapy48 citations Open access

   Semantic Scholar

   Save

10. Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy.

    Man-Fung Yuen, J. Heo, H. Kumada, F. Suzuki +28 more

    2022Journal of Hepatology45 citations Open access

    Semantic Scholar

    Save

11. Evaluation of the potent anti-hepatitis B virus agent (-) cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in a novel in vivo model

    Lynn D. Condreay, R. Jansen, T. Powdrill, L. Johnson +6 more

    1994Antimicrobial Agents and Chemotherapy40 citations Open access

    Semantic Scholar

    Save

12. A Randomized, Double‐Blind, Placebo‐Controlled, First‐Time‐in‐Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of GSK3389404 in Healthy Subjects

    Kelong Han, J. Cremer, R. Elston, S. Oliver +13 more

    2019Clinical pharmacology in drug development36 citations Open access

    Semantic Scholar

    Save

13. Effects of antileukemia agents on nuclear matrix-bound DNA replication in CCRF-CEM leukemia cells.

    Daniel J. Fernandes, Cecil Smith-Nanni, M. Paff, Toni-Ann M. Neff

    1988Cancer Research35 citations

    Semantic Scholar

    Save

14. TheAnti-Hepatitis B VirusActivities, Cytotoxicities, andAnabolic Profiles ofthe(-) and(+)Enantiomers ofcis-5-Fluoro-1-

    M. Paff, L. Frick, L. Wilson, Lynn D. Condreay

    199230 citations

    Semantic Scholar

    Save

15. (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine (524W91) inhibits hepatitis B virus replication in primary human hepatocytes

    Lynn D. Condreay, J. Condreay, R. Jansen, M. Paff +1 more

    1996Antimicrobial Agents and Chemotherapy19 citations Open access

    Semantic Scholar

    Save

16. Preclinical and Phase 1 Assessment of Antisense Oligonucleotide Bepirovirsen in Hepatitis B Virus–Transgenic Mice and Healthy Human Volunteers: Support for Clinical Dose Selection and Evaluation of Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses

    Kelong Han, D. Theodore, Gina McMullen, E. Swayze +7 more

    2022Clinical pharmacology in drug development18 citations Open access

    Semantic Scholar

    Save

17. Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection.

    Jin-Lin Hou, Seng G. Lim, M. Buti, M.-F. Yuen +44 more

    2026New England Journal of Medicine17 citations Open access

    Semantic Scholar

    Save

18. Bepirovirsen, antisense oligonucleotide (ASO) against hepatitis B virus (HBV), harbors intrinsic immunostimulatory activity via Toll-like receptor 8 (TLR8) preclinically, correlating with clinical efficacy from the Phase 2a study

    Shihyun You, Jared L. Delahaye, Megan E. Ermler, Jenn Singh +6 more

    2022Journal of Hepatology17 citations

    Semantic Scholar

    Save

19. GSK2878175, a pan‐genotypic non‐nucleoside NS5B polymerase inhibitor, in healthy and treatment‐naïve chronic hepatitis C subjects

    S. Gardner, Joseph Kim, S. Baptiste-Brown, Vincent A Lopez +8 more

    2018Journal of Viral Hepatitis12 citations

    Semantic Scholar

    Save

20. Immunomodulation by bepirovirsen may induce killing of infected hepatocytes (B-Together study)

    S. Joshi, J. Freudenberg, Jenn Singh, William T. Jordan +5 more

    2025Hepatology International11 citations Open access

    Semantic Scholar

    Save

21. Synthesis and distribution of primer RNA in nuclei of CCRF-CEM leukemia cells.

    M. Paff, Daniel J. Fernandes

    1990Biochemistry11 citations

    Semantic Scholar

    Save

22. Preclinical Development of Eniluracil: Enhancing the Therapeutic Index and Dosing Convenience of 5-Fluorouracil

    M. Paff, D. Baccanari, S. T. Davis, Shou-Song Cao +3 more

    2000Investigational new drugs10 citations

    Semantic Scholar

    Save

23. Safety, Tolerability, Pharmacokinetics, and Acceptability of Oral and Long-Acting Cabotegravir in HIV-Negative Chinese Men

    Kelong Han, P. Wannamaker, Hongzhou Lu, Biao Zhu +4 more

    2022Antimicrobial Agents and Chemotherapy9 citations Open access

    Semantic Scholar

    Save

24. Efficacy and safety of bepirovirsen in patients with chronic hepatitis B virus infection not on stable nucleos (t)ide analogue therapy: interim results from the randomised phase 2b B-Clear study

    Man-Fung Yuen, R. Pleśniak, Seng G. Lim, K. Tsuji +25 more

    2022Journal of Hepatology8 citations

    Semantic Scholar

    Save

25. Bepirovirsen induces innate immune activation in the liver potentially through TLR8 signaling

    Megan E. Ermler, Jared L. Delahaye, William Jordan, U. Nivarthi +14 more

    2026JHEP Reports5 citations Open access

    Semantic Scholar

    Save

26. Validation of fluorouracil metabolite analysis in excised tumor. Lability of anabolites.

    James R. Bading, A. Shahinian, M. Paff, P. Yoo +1 more

    2000Biochemical Pharmacology5 citations

    Semantic Scholar

    Save

27. Pegylated interferon reduces relapses following bepirovirsen treatment in participants with chronic hepatitis B virus infection on nucleos(t)ide analogues: end of study results from the Phase 2b B-Together study

    Maria Buti, Jeong Heo, Yasuhito Tanaka, P. Andreone +33 more

    202440. Jahrestagung der Deutschen Arbeitsgemeinschaft zum Studium der Leber4 citations

    Semantic Scholar

    Save

28. B-Clear Phase 2b Study Design: Establishing the Efficacy and Safety of Bepirovirsen in Patients with Chronic Hepatitis B Virus Infection

    J. Cremer, R. Elston, F. Campbell, S. Kendrick +3 more

    2023Advances in Therapy4 citations Open access

    Semantic Scholar

    Save

29. Comparison of Pharmacokinetics of the GalNAc-Conjugated Antisense Oligonucleotide GSK3389404 in Participants with Chronic Hepatitis B Infection across the Asia-Pacific Region

    Kelong Han, Hiroshi Ito, R. Elston, J. Cremer +3 more

    2022Antimicrobial Agents and Chemotherapy4 citations Open access

    Semantic Scholar

    Save

30. China-United States Research Collaborations in Antimicrobial Resistance.

    D. van Duin, Peidi Gu, Jane Dong, M. Paff +9 more

    2018Clinical Infectious Diseases4 citations Open access

    Semantic Scholar

    Save

31. Single nucleotide polymorphisms in the bepirovirsen binding site have limited impact on treatment response in chronic hepatitis B.

    J. Bouquet, Scott D. Speer, Alexander Koenig, Christine M. Livingston +12 more

    2026Journal of Hepatology3 citations Open access

    Semantic Scholar

    Save

32. WED-364 High-dimensional analysis of flow cytometry data reveals differences in post-treatment frequencies of naïve B cells, CD56dim natural killer cells, and terminally differentiated effector memory CD8+ T cells in responders versus nonresponders to bepirovirsen

    T. Hogan, Eduardo Gomez Castaneda, E. P. García, R. Barnard +4 more

    2024Journal of Hepatology3 citations

    Semantic Scholar

    Save

33. Evidence of durable response to bepirovirsen in B-Clear responders: B-Sure first annual report

    A. Gadano, Manuela Arbune, Masanori Atsukawa, S. Fujiyama +23 more

    2023Journal of Hepatology3 citations

    Semantic Scholar

    Save

34. Cell-mediated immunity analysis to assess the characteristics of immune response to bepirovirsen: Examples from the B-Clear study

    Jenn Singh, B. Salaun, Shihyun You, S. Corson +2 more

    2023Journal of Hepatology3 citations

    Semantic Scholar

    Save

35. Intrahepatic and peripheral immunophenotyping of participants with chronic hepatitis B receiving bepirovirsen in the B-Fine study strongly suggests that bepirovirsen may trigger a humoral response

    A. Boonstra, A. Gehring, Y. Ghosheh, N. Alatrakchi +18 more

    2026Zeitschrift für Gastroenterologie - German Journal of Gastroenterology2 citations

    Semantic Scholar

    Save

36. Lack of Pharmacokinetic Drug–Drug Interactions Between Bepirovirsen and Nucleos(t)ide Analogs

    Kelong Han, Amir S. Youssef, Mindy Magee, Steve Hood +5 more

    2025Clinical pharmacology in drug development2 citations Open access

    Semantic Scholar

    Save

37. A primary human hepatocyte system to evaluate antisense oligonucleotide activity against clinically identified hepatitis B virus variants that contain mismatches in the bepirovirsen binding site

    Alexander Koenig, Jerome Bouquet, E. Angelini, M. Savarese +6 more

    2023Journal of Hepatology2 citations

    Semantic Scholar

    Save

38. Combination treatment of a PAPD5/7 inhibitor with an antisense oligonucleotide bepirovirsen with concurrent dosing shows additive HBsAg decreases in the AAV-HBV mouse model

    Jared L. Delahaye, E. Long, Chi‐Hian Lau, J.T. Parsons +5 more

    2022Journal of Hepatology2 citations

    Semantic Scholar

    Save

39. Bepirovirsen induces innate immune proteins independent of HBV

    Jared L. Delahaye, S. You, Kai Fu, Scott Van Buren +12 more

    2026Hepatology International1 citations Open access

    Semantic Scholar

    Save

40. Evidence of durable response to bepirovirsen in B-Clear On-NA responders: B-Sure second report

    S. Lim, T. Asselah, G. Diaconescu, A. Gadano +17 more

    2025Digestive and Liver Disease1 citations

    Semantic Scholar

    Save

41. TOP-268 Up to 2 years’ functional cure in response to bepirovirsen therapy in B-Clear Not-on-NA responders: B-Sure third report

    Seng G. Lim, Manuela Arbune, Masanori Atsukawa, Stuart R. Flanagan +18 more

    2025Journal of Hepatology1 citations

    Semantic Scholar

    Save

42. WED-370 Bepirovirsen immune mechanism of action may potentiate infected hepatocyte killing: indirect evidence from B-together peripheral longitudinal biomarker analysis

    S. Joshi, J. Freudenberg, Jenn Singh, L. Felton +4 more

    2024Journal of Hepatology1 citations

    Semantic Scholar

    Save

43. Frequency of bepirovirsen binding site nucleotide polymorphisms at baseline and impact on end of treatment response to bepirovirsen (Phase 2b B-Clear study)

    Jerome Bouquet, R. Elston, P. Yates, Shihyun You +7 more

    2023Journal of Hepatology1 citations

    Semantic Scholar

    Save

44. Deep learning cluster analysis reveals subtypes in response to antisense oligonucleotide therapy in chronic hepatitis B

    C. Weis, Maria Littmann, Aleksei Triastcyn, William Jordan +5 more

    2023Journal of Hepatology1 citations

    Semantic Scholar

    Save

45. Mechanistic pharmacokinetics/pharmacodynamics modelling of the simultaneous effects of bepirovirsen on hepatitis B surface antigen and alanine transaminase changes in chronic hepatitis B patients: phase 2b analysis to inform phase 3 decision-making

    Amir S. Youssef, Mohamed Ismail, M. Magee, D. Theodore +3 more

    2022Journal of Hepatology1 citations

    Semantic Scholar

    Save

46. WED-577 Up to 24 months durability of functional cure in response to bepirovirsen plus Peg-IFN sequential therapy in B-Together responders: results from the B-Sure study

    C. Coffin, P. Andreone, Joaquín Cabezas, S. Gordon +21 more

    2026Journal of Hepatology0 citations

    Semantic Scholar

    Save

47. WED-585 Functional analysis of clinically observed SNPs in the bepirovirsen binding site reveals reduced HBV fitness via impaired HBx/HBV polymerase activity in vitro

    Alexander Koenig, Christine Livingston, J. Bouquet, Michael Savarese +8 more

    2026Journal of Hepatology0 citations

    Semantic Scholar

    Save

48. P197 Up to 36 months durability of functional cure in response to bepirovirsen therapy in B-clear not-on-NA responders: results from the B-sure study

    Stuart Flanagan, Seng G. Lim, T. Asselah, Gheorghe Iulian Diaconescu +19 more

    2026P197 Up to 36 months durability of functional cure in response to bepirovirsen therapy in B-clear not-on-NA responders: results from the B-sure study0 citations Open access

    Semantic Scholar

    Save

49. WED-587 Up to 36 months durability of functional cure in response to bepirovirsen therapy in B-Clear Not-on-NA responders: results from the B-Sure study

    Seng G. Lim, Manuela Arbune, Masanori Atsukawa, Stuart Flanagan +24 more

    2026Journal of Hepatology0 citations

    Semantic Scholar

    Save

50. O8 Clinically meaningful rates of functional cure in virologically suppressed patients with chronic hepatitis B infection treated with bepirovirsen: B-well phase 3 trials

    Jin-Lin Hou, Seng G. Lim, M. Buti, M.-F. Yuen +44 more

    2026O8 Clinically meaningful rates of functional cure in virologically suppressed patients with chronic hepatitis B infection treated with bepirovirsen: B-well phase 3 trials0 citations Open access

    Semantic Scholar

    Save